EMEA-001758-PIP01-15-M02

Key facts

Invented name
Active substance
Lumicitabine
Therapeutic area
Infectious diseases
Decision number
P/0362/2017
PIP number
EMEA-001758-PIP01-15-M02
Pharmaceutical form(s)
Powder for oral suspension
Condition(s) / indication(s)
Treatment of lower respiratory tract disease caused by human respiratory syncytial virus
Route(s) of administration
  • Oral use
  • Gastric use
Contact for public enquiries
Janssen-Cilag International NV
Tel. + 32 1460 2111
E-mail: contact@janssen-emea.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating